Annual report pursuant to Section 13 and 15(d)

Quarterly Data (Unaudited) (Details)

v3.8.0.1
Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenue $ 2,453 $ 1,597 $ 1,867 $ 1,436 $ 2,587 $ 1,596 $ 1,552 $ 8,486 $ 7,353 $ 14,221 $ 8,661
Gross profit 777 544 396 352 843 403 203 1,498 2,069 2,947 1,179
Net loss (8,978) (6,335) (5,507) (8,302) (5,576) (8,478) (5,765) (3,651) (29,122) (23,470) (19,590)
Net loss applicable to common shareholders $ (8,978) $ (6,335) $ (5,507) $ (8,302) $ (5,576) $ (11,494) $ (9,970) $ (6,775) $ (29,122) $ (33,815) [1] $ (24,245)
Basic and diluted net loss per share (In dollars per share) [2] $ (0.15) $ (0.18) $ (0.22) $ (0.38)              
Basic net loss per share (In dollars per share)         $ (0.29) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2] $ (0.82) $ (1.87) [1] $ (1.66)
Diluted net loss per share (In dollars per share)         $ (0.35) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2] $ (0.82) $ (2.05) [1] $ (1.83)
[1] Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
[2] Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.